# Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma

> **NCT00994643** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 11 (actual)

## Conditions studied

- High Risk Non-Hodgkin's Lymphoma

## Interventions

- **BIOLOGICAL:** Rituximab
- **BIOLOGICAL:** Interleukin-2

## Key facts

- **NCT ID:** NCT00994643
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02-05
- **Primary completion:** 2014-06-25
- **Final completion:** 2015-06-25
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00994643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00994643, "Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00994643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*